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Background and Objective. Various venom immunotherapy (VIT) protocols are available for Hymenoptera allergy. Although
adverse reactions (ADRs) to VIT are widely reported, controlled trials are still needed. We conducted a randomized prospective
study to evaluate ADRs and the eﬃcacy of three VIT regimens. Methods. 76 patients with Hymenoptera allergy, aged 16–76 years,
were randomized to receive an ultrarush protocol (group A: 27 patients), a rush protocol (group B: 25), or a slow protocol (group
C: 24). Aqueous venom extract was used in incremental phase and an adsorbed depot in maintenance phase. ADRs and accidental
Hymenoptera stings during VIT were used to evaluate eﬃcacy. Results. During incremental treatment, ADRs occurred in 1.99%,
3.7%, and 3.9% of patients in groups A, B, and C, and in 0.99%, 1.46%, and 2.7%, respectively, during maintenance. ADRs were
signiﬁcantly fewer in group A (incremental + maintenance phase) than in group C (1.29% versus 3.2%; P = 0.013). Reactions to
accidental Hymenoptera stings did not diﬀer among groups (1.1%, 1.2%, and 1.1%). Conclusion.U l t r a r u s hw a sa se ﬀective as the
rush and slow protocols and was associated with a low incidence of reactions to stings. This study indicates that ultrarush VIT is a
valid therapeutic option for Hymenoptera allergy.
1.Introduction
Reactions to stings by Hymenoptera species (Apis mellifera
and Vespula Species) are classiﬁed as normal local reactions,
large local reactions (LLRs), systemic anaphylactic reactions
(SARs), systemic toxic reactions, and unusual reactions [1].
All patients who have had an SAR to Hymenoptera stings
should avoid insects that sting; they should also carry ep-
inephrine for emergency self-administration, undergo ex-
amination for IgE antibodies speciﬁc for insect venom, and
be considered candidates for venom immunotherapy (VIT)
[1, 2]. Immunotherapy with puriﬁed Hymenoptera venom
reduces the risk of anaphylactic reactions in most patients
[2]. The primary goal of VIT is to prevent life-threatening
reactions. A secondary beneﬁt is that it helps relieve anxiety
about insect stings and improves quality of life [3, 4]. The
chance of a subsequent sting causing a more severe reaction
than previous sting-induced reactions may be just 1% [5, 6].
Furthermore, a too short interval between stings increases
the risk of a systemic reaction [7].
In recent decades, a number of VIT protocols have been
proposed with the aim of reducing the number of injections,
visits, and risk of SAR [2, 4, 8–10]. Among the various strat-
egies devised to desensitize patients with SAR, an ultrarush2 Journal of Allergy
Table 1: Protocol of incremental treatment for ultrarush∗, rush§, and slow conventional therapy∗.
Group A Group B Group C
µg/dose Cumulative µg/dose Minute µg/dose Cumulative µg/dose Day Hour µg/dose Cumulative µg/dose Week
0.001 0.001 0 0.01 0.01 1 0 0.02 0.02 1
0.01 0.011 15 0.1 0.11 2 0.04 0.06 2
0.04 0.051 30 1 1.11 4 0.08 0.14 3
0.05 0.11 45 2 3.11 6 0.2 0.34 4
0.1 0.21 60 3 5.11 2 0 0.4 0.74 5
0.4 0.61 75 3.5 9.61 2 0.8 1.54 6
0.5 1.11 90 3.5 13.11 4 2 3.54 7
1 2.11 105 10 23.11 3 0 4 7.54 8
4 6.11 120 15 38.11 2 8 15.54 9
5 11.11 135 15 53.11 4 10 25.54 10
10 21.11 150 20 73.11 4 0 20 45.54 11
40 61.11 165 25 98.11 2 40 85.54 12
50 111.101 180 25 123.11 4 60 145.54 13
30 153.11 5 0 80 225.54 14
35 188.11 2 100 325.54 15
35 223.11 4
∗As reported in Patella et al. [22].
§As reported in Bil` oe ta l .[ 23].
protocol has been proposed as an alternative to rush and
slow protocols in children, adolescents, and adults [11–18].
One advantage of rapid complete desensitization could be
to reduce the risk of relapse of anaphylaxis if the patient is
stung before the induction phase is completed. Rush therapy
should be indicated for patients with moderate and frequent
SAR at a high risk of frequent stings [14] and for patients
with a single episode of SAR, but high psychological involve-
ment [1, 13, 19, 20]. Although VIT-associated ADRs have
beenwidely reported, there is a need forcontrolled,random-
ized trials that directly compare diﬀerent regimens, that is,
weekly, rush and ultrarush protocols, to determine whether
the ultrarush VIT protocol is well tolerated and eﬀective in
patients with Hymenoptera sting-induced SAR.
The aim of this study was to evaluate, in a randomized
controlled trial, the risk of adverse reactions (ADRs) and the
eﬃcacyofanultrarushprotocolcomparedtorushandweek-
ly regimens in patients allergic to the Hymenoptera species,
Apis mellifera or Vespula Species, commonly known as honey
bee (HB) and yellow jacket (YJ).
2. Methods
2.1. Study Design. Patients with an indication for VIT were
treated with commercially available preparations of Hymen-
optera venom extracts and monitored for at least 24 months
to record side eﬀects and eﬃcacy. According to three
diﬀerent treatment schedules (Table 1), the patients received
injections of an aqueous extract of Hymenoptera venom
(AquagenSQ, ALK-Abell´ o, Hørsholm, Denmark) during the
incremental stage of treatment and a puriﬁed aluminium-
adsorbed depot extractof Hymenoptera venom (AlutardSQ,
ALK-Abell´ o) during the maintenance stage. Both prepara-
tions were certiﬁed and prepared from the same source by
the supplier (ALK-Abell´ o). The venom was puriﬁed by a
Sephadex-gelﬁltrationprocessbywhichtheproteinfractions
are separated according to molecular weight. Venom extracts
do not contain vasoactive amines. In addition, the extract
undergoes ﬁltration to reduce the presence of small peptides
like apamin, kinins, and mast cell degranulating peptides.
For depot VIT, the raw venom undergoes the same puriﬁ-
cation procedure that results in the recovery of a fraction
containing only allergen, which is subsequently adsorbed
ontoaluminumhydroxide.Allpreparationscontainthesame
amount of allergens, that is, 100µg/mL, as speciﬁed by
the manufacturer (ALK-Abell´ o). This ensured homogeneous
immunogenicity. Injections were carried out according to
EAACI Position Papers [2, 21].
2.2. Cohort and Randomization of Patients. Seventy six
patients(51males,25females;aged16–76years)withhistory
of SAR to HB or YJ venom were randomly assigned to
diﬀerent treatment for VIT as reported in Table 2. Patients
were randomly assigned to group A, B, or C using a com-
puter-generated random list and numbered envelopes. The
envelopes were opened immediately before the start of
venom immunotherapy. Patients of groups A (n = 27), B
(n = 25), and C (n = 24) were treated with an ultrarush,
rush, and weekly protocol, respectively. Groups A and B were
admitted to hospital for VIT injections. Adverse reactions
were graded according to M¨ uller’s classiﬁcation [1, 9].
2.3. Incremental and Maintenance Phases. Group A patients
were treated with a three-hour ultrarush protocol (Table 1a)
[22]. Patients underwent continuous measurements of
oxygen saturation and repeated measurements of blood
pressure. The cumulative dose of Hymenoptera venom (HB
or YJ) at the end of the incremental phase was 111.101µg.Journal of Allergy 3
Table 2: Demographic and clinical data of the 76 patients enrolled in the study.
Group N = Treatment Vespula/Apis Sex (M/F) Age
(range)
Age
(mean)
Local large
reactions∗
Systemic
allergic
reactions§
Grade§
(I) (II) (III) (IV)
A 27 Ultrarush 18/9 19/8 16–76 39.1 1 26 (3) (3) (12) (8)
B 25 Rush 16/9 16/9 18–68 40.3 1 24 (5) (4) (13) (2)
C2 4 Slow
Conventional 16/8 16/8 19–69 38.6 2 22 (2) (6) (10) (4)
Total 76 — 50/26 51/25 16–76 39.3 4 72 (10)(13)(35)(14)
∗It is deﬁned as a swelling exceeding a diameter of 10cm which lasts longer than 24h.
§Classiﬁed according to M¨ uller [9]: grade I: urticaria, pruritus, and malaise; grade II: angioedema, chest tightness, nausea, vomiting, abdominal pain, and
dizziness; grade III: dyspnoea, wheeze, stridor, dysphagia, and hoarseness; grade IV: hypotension, collapse, loss of consciousness, incontinence, and cyanosis.
Thirty minutes after the last injection, patients were dis-
chargedtohome.Subsequently,onday15,andonceamonth
thereafter,thepatientsofeachgroupreceivedasubcutaneous
injection of 50µg adsorbed preparation on each arm,
according to the parameter reported by the manufacturer
(ALK Abell´ o, Milan, Italy): 100µg of aqueous preparation =
100000SQ units of aluminum-adsorbed depot preparation.
GroupBpatientsreceivedtheaqueouspreparationaccording
to a daily rush schedule as reported in Table 1 (Group B)
[23]. Group C was treated weekly with the slow conventional
protocol shown in Table 1 (Group C) [22]. The cumulative
doses of venom extract during the incremental phase in each
group exceeded 100mcg. No patient enrolled in this study
received premedication before VIT.
2.4.SkinPrickTest. Askintestwasdoneinallpatientsatleast
three weeks after the last sting [1, 24–26]. Sensitization was
detected by skin prick tests with concentrations of 1, 10, and
100µg/mL of Hymenoptera venom. If the prick test was neg-
ative, an intradermal test was done with 0.02mL of venom
concentrations from 0.001 to 1µg/mL,injected into the volar
surface of the forearm. The concentration was increased in
10-fold increments until there was a positive response or up
to a maximum concentration of 1µg/mL. Skin response was
assessed after approximately 15–20 minutes. Physiological
salineandhistaminedihydrochloride0.1%servedasnegative
and positive controls, respectively.
2.5. IgE Assay. Total and speciﬁc IgE were measured in the
patients’ serum at diagnosis and 6, 12, 18, and 24 months
after reaching the maintenance dose, using the Immulite
2000 Allergy system, according to the manufacturer’s in-
structions (Diagnostic Products Corporation). The linear
range of the assay was 0.2–100kU/L for the Immulite
2000sIgE method [27, 28].
2.6. Evaluation of Tolerance and Eﬃcacy. Tolerance to VIT
was evaluated on the basis of the ADRs recorded during the
immunotherapy. The adverse reactions were classiﬁed as a
large local reaction when there was swelling with a diameter
more than 10cm at the injection site that lasted for more
than 24 hours (i.e., an LLR), or as a systemic anaphylactic
reaction of diﬀerent grades, as reported in M¨ uller’s classiﬁ-
cation [9]. The eﬃcacy of VIT was evaluated on the basis
of the outcome when a patient was accidentally restung by
a Hymenoptera species. Patients were asked to report any
of such stings during and after the VIT, and the type of
reaction,accordingtoM¨ uller’sclassiﬁcation[9].Eachpatient
had followup visits at the start of VIT and at 6, 12, 18, and 24
months thereafter from start of maintenance phase.
2.7. Statistical Analysis. Results are expressed as means ±
SEM. Treatment groups (A, B, and C) and shift of prepara-
tions (from aqueous to depot) were compared. Categorical
variables were compared by the chi-square test. Trends
within a patient group were quantiﬁed by the Wilcoxon
signed rank test. When the data were subjected to linear cor-
relation analysis, correlations were calculated using the
Spearman rank coeﬃcient (rs) [29]. The level of statistical
significance was P<0.05.
3. Results
3.1. Tolerance of Each Venom Immunotherapy Regimen.
Duringtheincrementalphaseofvenomimmunotherapy,the
numbers of LLR (deﬁned as a swelling of more than 10cm
in diameter, lasting longer than 24h) [9] were 7 out of 351
injections in group A (1.99%); 12/375 in group B (3.2%);
13/356ingroupC(3.6%)(Figure1).Duringtheincremental
phase, no SAR occurred in patients in group A (0/351
injections); two SARs occurred in group B (2/375; 0.9%
of injections); one in group C (1/356; 0.56% of injections)
(Figure 2). The rate of ADRs did not diﬀer among the three
groups: group A 7/351 (1.99%); group B 14/375 (3.7%);
group C 14/356 (3.9%); (P = 0.27). During the incremental
phase, two patients of group C withdrew from the study (at
the fourth and seventh weeks). Adverse reactions were not
the reasons for withdrawal. No patients in groups A and B
withdrew from the trial.
In agreement with previous reports [30, 31], SARs
occurred more frequently during the maintenance phase in
patientswiththeHBvenompreparationthaninthosereceiv-
ing the YJ preparation (Table 3). In the maintenance phase,
the ADRs were as follows: group A 8/810 (ADR/injections)
(0.99%); group B 11/750 (1.46%); group C 12/440 (2.7%);
P = 0.035; A versus C, P = 0.02; B versus C, (P = 0.03).
During the whole study (incremental phase + mainte-
nance phase), the ultrarush protocol (group A) resulted in4 Journal of Allergy
Table 3: Side eﬀects of patients treated with maintenance dose.
Group A Group B Group C Total
Patients 1 7 6 14
maintenance dose of Apis m. 165 1 2
maintenance dose of Vespula spp. 11 2
Local large reaction∗ (%) — 2 (33.3) 4 (66.6) 6
Systemic anaphylactic reaction§ (%) 1(12.5) 5 (62.5) 2 (25.0) 8
Grade I 1 4 1 6
Grade II — 1 1 2
∗A large local reaction is deﬁned as a swelling at the site of more than 10cm lasting for more than 24 hours [31].
§A systemic anaphylactic reaction (SAR) was classiﬁed with modiﬁed classiﬁcation of M¨ uller [9].
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Figure 1: Frequency of local side eﬀects in three groups of
patients treated according to diﬀerent venom immunotherapy
(VIT) protocols (see Methods for treatments). Results are shown
per injections () and per patients (). Each bar represents the
mean ± SEM. ∗P<0.05 compared with the corresponding group
Av e r s u sg r o u pB .∗∗P<0.001 compared with the corresponding
group A versus group C.
less ADRs than the slow protocol (group C) (1.29% versus
3.2%; (P = 0.013)).
3.2. Shifting from the Incremental to the Maintenance Phase.
No severe ADRs were observed when patients in groups A,
B, and C were shifted from the aqueous preparations used
during the incremental phase to adsorbed preparations for
maintenance, which is in accordance with a previous report
[32]. Rates of reactions were similar in each group: group
A 1/27 (gastrointestinal symptoms 1), group B 2/25 (LLR 1;
gastrointestinal symptoms 1), and group C 1/24 (headache
1).
3.3. Total and Speciﬁc IgE Levels and Evaluation of Serum
s-IgE/Total IgE Ratio with SAR. Total and speciﬁc IgE was
monitored before starting VIT, at the end of VIT, and
during the study in the three groups (Figures 3 and 4). The
serum s-IgE/total IgE ratio has been reported to predict the
clinical response to allergen-speciﬁc immunotherapy [33].
We compared the serum s-IgE/total IgE ratio in our three
groups of patients using the number of SARs before VIT
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Figure 2: Frequency of systemic side eﬀects in three groups
of patients treated according to diﬀerent venom immunotherapy
(VIT) protocols. Results are shown per injections ()o rp e r
patients (). Each bar represents the mean ± SEM. ∗P<0.001
compared with the corresponding group A versus group B. ∗∗P<
0.05 compared with the corresponding group A versus group C.
and after hymenoptera sting during the maintenance phase.
There was a similar highly signiﬁcant direct correlation
between the sIgE/tIgE post/preultrarush VIT delta and
the SAR pre/postultrarush VIT delta in the three groups
considered: group A (rho = 0.79; P = 0.034, Spearman rank
c o r r e l a t i o nt e s t ) ,g r o u pB( r h o= 0.83; P = 0.039, Spearman
rank correlation test), and group C (rho = 0.77; P = 0.041,
Spearman rank correlation test).
3.4. Eﬃcacy of Venom Immunotherapy. Accidental Hymen-
optera stings during VIT were used to evaluate the eﬃcacy of
each of the three desensitization protocols. Of the 76 patients
in the maintenance phase, 34 were restung accidentally, no
allergic reactions were reported in 23 patients of these 34
patients (group A: 8; group B: 7; group C: 8) (Table 4). In
the remaining 11 patients, there were three episodes of LLR
and one of SAR (group A), three episodes of LLR and one of
SAR (group B), and C two episodes of LLR and one of SAR
(group C) (Table 4).Journal of Allergy 5
Table 4: Allergic reactions to a ﬁeld sting.
Group A Group B Group C Total
Patients restung 13 10 11 34
maintenance dose of Apis m. 967 2 2
maintenance dose of Vespula spp. 444 1 2
No local and systemic eﬀects 8 7 8 23
Local large reaction∗ 332 8
Systemic anaphylactic reaction§ 111 3
Grade I — 1 1
Grade II 1 — 1 2
Grade III — — — —
Grade IV — — — —
∗A large local reaction is deﬁned as a swelling at the site of more than 10cm lasting for more than 24 hours.
§A systemic anaphylactic reaction (SAR) was classiﬁed with modiﬁed classiﬁcation of M¨ uller [9].
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Figure 3:TotalIgEduringtheincrementalandmaintenancephases
in group A (Vespidae 18; Apidae 9; n = 27), group B (Vespidae 16;
Apidae 9; n = 25), and group C (Vespidae 16; Apidae 8; n = 24).
Vertical bars indicate the mean ± SEM.
4. Discussion
Various protocols have been proposed to obtain rapid
desensitization of patients allergic to Hymenoptera venom
[11, 12], but how to increase rapidly the doses is still
debated. Some studies reported a high risk of ADR with
rush protocols [31, 34, 35], while other studies showed that
t h e yw e r es a f e[ 13–15, 36–40]. In contrast with a previous
study in which systemic reactions were found during the
incremental phase of an ultrarush VIT protocol [12], no
systemic reaction occurred in our group A patients, whereas
they occurred in both groups B and C patients. However, in
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Figure 4: Speciﬁc IgE during the incremental and maintenance
phases in group A () (Vespidae 18; Apidae: 9; n = 27), group B
() (Vespidae 16; Apidae 9 n = 25), and group C () (Vespidae 16;
Apidae 8; n = 24). Bars indicate the mean ± SEM.
the maintenance phase, there was a case of SAR in group A,
5 in group B, and 2 in group C. We are unable to explain
theseﬁndings;notwithstanding,nopretreatment,intermsof
antihistamines and corticosteroids, was administered in our
patients, unlike several previous studies [40, 41].
A wide range of systemic reactions have been reported
during the incremental phase of VIT. Birnbaum et al. used
an ultrarush VIT protocol similar to ours to treat 258 Hy-
menoptera venom-allergic patients with a cumulative dose
of 101.1µg, administered over a period of 3.5 hours. In
325 ultrarush immunotherapies performed, 33 (12.79%)
patients experienced a systemic reaction during dose incre-
ment, namely, localized urticaria and/or angioedema and/or
erythema in 24 patients and hypotension in 9 patients [14].
Bernsteinetal.reportedmildsystemicreactionsinonly5.2%6 Journal of Allergy
of 77 patients; however, all patients received a cumulative
total dose of only 58.55µg on one day followed by an
accelerated build-up over three weeks [38]. In our study, the
frequency of reactions was comparable with the low number
of ADRs observed in previous study, where the side eﬀects
during VIT were determined by percent of injections during
the incremental and the maintenance phases [34, 42].
In our study, during the maintenance phase, in agree-
ment with previous reports [30], ADRs occurred more fre-
quently in our patients treated with the HB venom prepa-
ration than in those receiving the YJ preparation. We pre-
viously found that ultrarush VIT rapidly decreased ICAM-1
levels in patients with Hymenoptera allergy [43]. It is likely
that the known ability of VIT to correct the imbalance in T
lymphocytesubpopulationsandintheassociatedproduction
of cytokines may account for the diﬀerent response to HB
versus YJ venom [43]. In fact, these cytokines include IL-4
and TNF-alpha, which upregulate adhesion molecules [44].
In particular, a shift in cytokine responses from a Th2 to
a Th1 pattern was demonstrated during rush VIT using
both HB [45] and YJ venom [46]. Regarding T-reg, a recent
study found an elevated IL-10 production by CD3(+) T
cells few hours after rush VIT [47]. In our study, patients
were treated with aqueous extracts of Hymenoptera venom
during the incremental phase and well tolerated the shift to
the maintenance dose with aluminum hydroxide-adsorbed
extracts, conﬁrming previous data [32, 48]. During VIT, the
incidence of ADRs due to restings was similar in all three
groups. The eﬃcacy of ultrarush therapy is therefore com-
parable with that of rush and slow conventional protocols.
After the incremental phase and also during maintenance
treatment, speciﬁc IgE levels changed to the same extent
in the three treatment groups, in agreement with other
studies [49, 50]. The ultrarush protocol signiﬁcantly reduced
total and speciﬁc IgE levels as the rush and conventional
protocol does. In all patients, there was a highly signiﬁcant
direct correlation between the sIgE/tIgE post/preultrarush
VIT delta and the SAR pre/postultrarush VIT delta, which
conﬁrms the eﬀectiveness of the three protocols.
Given our observation that the ultrarush VIT protocol is
welltoleratedandeﬀectivetogetherwiththefactthatpatients
could be vaccinated before the Hymenoptera season starts
[51], the fast protocol (3 hours) means patients have more
time available for social activities and work. The working
environment of some patients (beekeepers, farmers, etc.)
with Hymenoptera allergy is an adjunctive risk factor for
insect sting compared with the general population. Eﬀective
VIT frees these patients and their families from the worry
of stings. Because of its short duration, ultrarush VIT is
more easily accepted by the patients and has the additional
advantages of rapid protection with a low cost. VIT improves
the quality of life in all patients allergic to Hymenoptera
venom,particularlythoseintheM¨ ullerclassesIIIandIVand
in the people who have been restung during VIT [3, 19, 52].
In conclusion, ultrarush was as eﬀective as the rush and
slow conventional protocols and was associated with a low
incidence of reactions to Hymenoptera stings. This study
indicates that ultrarush VIT is a valid therapeutic option for
patients with Hymenoptera allergy.
Abbreviations
ADR: Adverse reaction
HVA: Hymenoptera venom allergy
LLR: Large local reaction
SAR: Systemic anaphylactic reaction
VIT: Venom immunotherapy.
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